ARROWHEAD PHARMACEUTICALS, INC. Cash and Cash Equivalents
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) had Cash and Cash Equivalents of $69.40 million as of 2024-06-30, per its 10-Q filed 2024-08-08.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2024-08-08
- 2024-06-30: Cash and Cash Equivalents, at Carrying Value $69.40M.
- 2024-03-31: Cash and Cash Equivalents, at Carrying Value $127.70M.
- 2023-12-31: Cash and Cash Equivalents, at Carrying Value $58.20M.
- 2023-06-30: Cash and Cash Equivalents, at Carrying Value $105.30M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2024-06-30 | $69.40M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $127.70M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $58.20M 10-Q · filed 2024-02-06 | |
| 2023-06-30 | $105.30M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $135.00M 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $202.20M 10-Q · filed 2023-02-06 | |
| 2022-06-30 | $139.44M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $86.41M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $91.59M 10-Q · filed 2022-02-02 | |
| 2021-09-30 | $184.43M 10-Q · filed 2022-08-04 | |
| 2021-06-30 | $325.98M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $372.38M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $139.92M 10-Q · filed 2021-02-04 | |
| 2020-09-30 | $143.58M 10-K · filed 2021-11-22 | $143.58M 10-K · filed 2020-11-23 |
| 2020-06-30 | $219.32M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $256.65M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $461.03M 10-Q · filed 2020-02-05 | |
| 2019-09-30 | $221.80M 10-K · filed 2020-11-23 | |
| 2019-06-30 | $188.33M 10-Q · filed 2019-08-05 | |
| 2019-03-31 | $161.64M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $189.77M 10-Q · filed 2019-02-07 | |
| 2018-09-30 | $30.13M 10-K · filed 2019-11-25 | |
| 2018-06-30 | $28.00M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $69.81M 10-Q · filed 2019-05-08 | |
| 2017-12-31 | $11.53M 10-Q · filed 2019-02-07 | |
| 2017-09-30 | $24.84M 10-Q · filed 2019-05-08 | |
| 2017-06-30 | $38.38M 10-Q · filed 2018-08-07 | |
| 2017-03-31 | $61.72M 10-Q · filed 2018-05-08 | |
| 2016-12-31 | $102.11M 10-Q · filed 2018-02-09 | |
| 2016-09-30 | $85.37M 10-K · filed 2018-12-11 | |
| 2016-06-30 | $43.62M 10-Q · filed 2017-08-03 | |
| 2016-03-31 | $50.30M 10-Q · filed 2017-05-03 | |
| 2015-12-31 | $62.17M 10-Q · filed 2017-02-06 | |
| 2015-09-30 | $81.21M 10-K · filed 2018-12-11 | |
| 2015-06-30 | $87.25M 10-Q · filed 2016-08-09 | |
| 2015-03-31 | $96.45M 10-Q · filed 2016-05-10 | |
| 2014-12-31 | $103.99M 10-Q · filed 2016-02-09 | |
| 2014-09-30 | $132.51M 10-K · filed 2017-12-12 | |
| 2014-06-30 | $138.35M 10-Q · filed 2015-08-04 | |
| 2014-03-31 | $142.85M 10-Q · filed 2015-05-11 | |
| 2013-12-31 | $59.71M 10-Q · filed 2015-02-09 | |
| 2013-09-30 | $19.11M 10-K · filed 2016-12-14 | |
| 2013-06-30 | $29.03M 10-Q · filed 2014-08-12 | |
| 2013-03-31 | $3.31M 10-Q · filed 2014-05-06 | |
| 2012-12-31 | $2.93M 10-Q · filed 2014-02-04 | |
| 2012-09-30 | $3.38M 10-K · filed 2015-12-14 | |
| 2012-06-30 | $2.28M 10-Q · filed 2013-08-07 | |
| 2012-03-31 | $3.60M 10-Q · filed 2013-05-09 | |
| 2011-12-31 | $6.77M 10-Q · filed 2013-02-13 | |
| 2011-09-30 | $7.51M 10-K · filed 2014-11-25 | |
| 2011-06-30 | $4.32M 10-Q · filed 2012-08-13 | |
| 2011-03-31 | $4.79M 10-Q · filed 2012-05-08 | |
| 2010-12-31 | $5.47M 10-Q · filed 2012-02-09 | |
| 2010-09-30 | $6.85M 10-K · filed 2012-12-28 | |
| 2010-06-30 | $8.98M 10-Q · filed 2011-08-08 | |
| 2009-09-30 | $2.02M 10-K · filed 2011-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |